BLISSGVS: Revenue up, net profit down; subsidiary sale and dividend declared, restructuring ahead

About this update from Bliss Gvs Pharma Limited

Revenue grew year-over-year, but consolidated net profit declined due to lower margins and exceptional items. Board approved sale of a step-down subsidiary and asset, and recommended a final dividend, with restructuring expected to impact H1 FY26.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bliss Gvs Pharma Limited